ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Genetic Technologies Ltd

Genetic Technologies Ltd (GENE)

0.75
0.0105
(1.42%)
Closed October 12 4:00PM
0.783
0.033
(4.40%)
After Hours: 7:35PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

GENE News

Official News Only

GENE Discussion

View Posts
zeusgodmd zeusgodmd 3 months ago
Whoโ€™s in charge of this one
๐Ÿ‘๏ธ0
willlbone willlbone 3 months ago
GENE under $1
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
GENE under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
GENE under $3
๐Ÿ‘๏ธ0
BurgerKing82 BurgerKing82 7 months ago
Fascinating how quiet this board is...people do realize less than 3 million OS,right?....This puppy will pop at some point...Imagine if 400-800k or more shares get bought up
๐Ÿ‘๏ธ0
realtmg realtmg 7 months ago
Took a position
๐Ÿ‘๏ธ0
Awl416 Awl416 7 months ago
What leaked?
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
GENE 10Q 2/27
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
GENE under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
GENE new 52 week low
👎️ 1 🩳 1
harry crumb harry crumb 10 months ago
Gene is now junk! Sold out this turd for end of year loss. Going nowhere but back under 1$
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
GENE new 52 week low
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 10 months ago
Maybe shorts going to cover before split
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 10 months ago
They are going to make a 60 cent stock 60$ seems a little crazy
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 11 months ago
I hope so
๐Ÿ‘๏ธ0
harry crumb harry crumb 11 months ago
Almost time for this to double
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 12 months ago
Somebody buy this company this is pathetic, but I did buy more today
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Its going to be the next bio dynasty! $$$$$
๐Ÿ‘๏ธ0
subslover subslover 1 year ago
NP man. This one is a starving wolf with flees. Smells bad too!
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 1 year ago
GENE: Admiral Subs, Orion Fleet Commander!! (SORRY for my belated replies here, but off today behind family matters; but MONSTER THANKS!! Will still toss bucks at some of your picks today, when they lock-in for launch or set-back.)
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
This company is the next merck! Enough said, buy em up now an wait it out. We loaded here an still adding
๐Ÿ‘๏ธ0
subslover subslover 1 year ago
News #2 GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, โ€œCompanyโ€, โ€œGTGโ€), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.

Highlights:

Results from the trial are expected to change the way risk is assessed and reshape the standard of care in general practice for serious disease.
The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
Results of this study could lead to a revision of national guidelines and improve risk stratification for four of the most common cancers in Australia; breast, colorectal, prostate, and melanoma.
The study will recruit nearly 600 participants from eight general practices across Victoria.
As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.
The project titled, โ€œThe CASSOWARY (CAncer genomic riSk ScOres in primARY Care) Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practiceโ€. This is a multi-institutional, multidisciplinary collaborative initiative with internationally recognised experts. Disciplines include academic, general practice and primary care trials, clinical genetics and genetic counselling, genetic/cancer epidemiology, health economics and modelling, biostatistics, implementation science, genomic test development and commercialisation, consumer investigators with lived experience of cancer and associate investigators with expertise in cancer policy with Cancer Australia. The Cassowary Trial is a collaboration between international investigators from GTG (Industry partner), University of Melbourne and Queen Mary University of London, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, and the Daffodil Centre.

The study will recruit a targeted cohort to create high quality evidence about the clinical utility and cost-effectiveness of using cancer polygenic risk scores, such as geneType multi-Test to tailor cancer screening and possible treatment in general practice.

Professor Jon Emery, the lead investigator of this study team, has an established history in genomics in Australian general practice and has been involved in national and international screening and cancer risk assessment guidelines. This funding is one of several trials that he leads, โ€œWe look forward to extending our work in the space of polygenic risk score implementation in general practice. Over the years, our team has created a framework for risk-assessment implementation in clinical practice, and with each subsequent study we are building our evidence to support a structured, real-world implementation strategy.โ€

This multi-year utility trial will focus on the implementation of four of geneTypeโ€™s multi-Test integrated polygenic risk scores: breast, colorectal, prostate, and melanoma. The trial will assess patient and provider behaviour, and assess the economic impact of the resulting behaviour.

GTGโ€™s Director of Scientific Affairs, Erika Spaeth, a co-investigator of the study said, โ€œWe are proud of our academic partnerships and honoured to be a part of the growing body of evidence showing the utility of polygenic risk in clinical care. We look forward to the implementation evidence outcomes that will result from this utility study.โ€

GTG has a strong history of research partnerships with academic institutions, including the University of Melbourne. The company is committed to its collaborative initiatives that support the evolution of predictive population healthcare. GTGโ€™s CEO, Simon Morriss noted, โ€œThis is an important step forward for preventive precision medicine. The results from the Cassowary Trial have the ability to support the clinical utility of geneType multi-Test and even more importantly provide compelling evidence for itsโ€™ inclusion into National Guidelines and standard of care. The results from this study will be a major leap forward for geneType.โ€

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
๐Ÿ‘๏ธ0
subslover subslover 1 year ago
Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare

MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessible for order in Australia, marking a significant milestone in the journey to redefine preventative healthcare.

Early 2023, GTG unveiled the tests in the United States, introducing three additional diseases to the already remarkable geneType Multi-Risk Test platform. Today, with immense pride, we share the news that these innovations, including assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, have been authorized for sale in Australia by National Association of Testing Authority (NATA). This expanded genetic test now offers a comprehensive evaluation of risk for a total of nine individual serious diseases, all extracted from a single, simple saliva sample.

The risk assessment panel revolves around Oncology, Cardiovascular, and Metabolic diseases, covering:

Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Melanoma
Colorectal Cancer
Diabetes
Coronary Artery Disease
Atrial Fibrillation
The approval granted by NATA follows the release in March by the Centers for Medicare & Medicaid (CMS) to offer the enhanced panel in the United States.

The expanded Multi-test panel caters to individuals of diverse ethnic backgrounds, focusing on those over the age of 30. Each of these newly incorporated diseases holds a significant threat to public health, with dire statistics calling for immediate attention.

According to the Australian Institute of Health and Welfare, 2023 is expected to witness approximately 10,639 new cases of melanoma, Australia's third most diagnosed cancer. Pancreatic cancer estimates are even grimmer, projecting 2,355 new diagnoses in 2023, with a staggering 87% mortality rate. Early identification of high-risk individuals for both melanoma and pancreatic cancer offers a vital window for early intervention, potentially saving countless lives.

In the case of atrial fibrillation (AFib), research indicates its impact on approximately 2% of the Australian population, equating to over 500,000 individuals. Detecting AFib early can pave the way for interventions that improve patient outcomes, extend life expectancy, and save lives.

Simon Morriss, CEO of GTG, states, "Securing approval for the expanded version of the Multi-test in Australia underscores GTG's unwavering dedication to lead the world in delivering personalized risk assessments, thereby enabling population wide preventative healthcare for a range of serious diseases."

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

https://www.globenewswire.com/newsroom/ti?nf=ODkxOTY4MyM1ODA3MzA2IzIwNTAwMzg=
https://ml.globenewswire.com/media/OGNiZWVkYTQtMzlkYy00ZjIwLTlmNjEtYjE3OTUyODM4YjgyLTEwNjE2MDk=/tiny/Genetic-Technologies-Ltd.png

Source: Genetic Technologies Ltd
© 2023 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 1 year ago
Harry I hope you right this company should be bought out by Merck or someone with big cancer portfolio
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
5$ coming, load now, going to go up
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Breakout coming
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
GENE new 52 week low
๐Ÿ‘๏ธ0
harry crumb harry crumb 1 year ago
Watching this for a big jump
๐Ÿ‘๏ธ0
1idiotinvestor 1idiotinvestor 1 year ago
I watched the clip on Balancing Act about breast Cancer and "Gene Type". Very good news.
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 1 year ago
Advertising starting only up from here
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 1 year ago
They where going to start selling campaign in us in may will see
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Stock should be 5 to 10$ by now. Sell company to highest bidder
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
This is going to pop big one of these days
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Have to read up on seeing alpha web site the meeting itโ€™s typed up. Big things planned for marketing in USA. Big meeting in Montreal Canada in May. Buy your shares now and watch. Nice after hours movement
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Pfizer in talks to buy seagen 30 billion for cancer drugs market too big not to buy gene
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
This ticker could be a huge winner! $$$$
The science is looking very promising
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Moderna in with life edit for gene manipulation matter of til phizer buys this beauty
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
Added an holding here
๐Ÿ‘๏ธ0
SmellMyFinger SmellMyFinger 2 years ago
Not giving financial advice though, right?
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
Hold hold add add
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Phizer or Merck oncology division will buy this out more diagnoses more money they make on chemotherapy. Big boys holding it down I go my shares for the ride
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Open up that report in new section shows there new path of advertisement and stuff with patents in countries
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
3$
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Letโ€™s see 4 to 6$ today folks big buys and pr blitzing occurring
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
I forgot it was also a ticker going across the screen on mad money last night
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Share outstanding I have 19 million does not seem like a lot with volume this week
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
Will see the bump at 830
๐Ÿ‘๏ธ0
zeusgodmd zeusgodmd 2 years ago
These test are usually 2500$ each maybe some donโ€™t know how much money this company is going to make worldwide with new results from Harvard will be a game changer
๐Ÿ‘๏ธ0
harry crumb harry crumb 2 years ago
This thing could really pop tomorrow, should be very active an agree huge volume may happen
๐Ÿ‘๏ธ0
saj saj 2 years ago
Bring on the volume!
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock